AChR Alpha3 Polyclonal Antibody

CHRNA3 encodes a member of the nicotinic acetylcholine receptor family of proteins. Members of this family of proteins form pentameric complexes comprised of both alpha and beta subunits. CHRNA3 encodes an alpha-type subunit, as it contains characteristic adjacent cysteine residues. The encoded protein (cholinergic receptor nicotinic alpha 3 subunit) is a ligand-gated ion channel that likely plays a role in neurotransmission. Polymorphisms in this gene have been associated with an increased risk of smoking initiation and an increased susceptibility to lung cancer. Alternatively spliced transcript variants have been described.

The ACHR ALPHA3 Polyclonal Antibody is a highly specific and reliable tool designed for the detection and analysis of the alpha-3 subunit of the acetylcholine receptor (ACHR). This antibody is produced through a rigorous process, ensuring its exceptional quality and performance.

With its polyclonal nature, this antibody exhibits a broad reactivity, making it suitable for various applications, including immunohistochemistry, immunofluorescence, and western blotting. Its exceptional specificity enables the precise identification and localization of the ACHR alpha-3 subunit in different tissues and cell types.

The ACHR ALPHA3 Polyclonal Antibody offers unparalleled sensitivity, allowing for the detection of low-abundance ACHR alpha-3 subunit proteins. Its high affinity ensures reliable and reproducible results, making it an ideal choice for both research and diagnostic purposes.

This antibody is manufactured using state-of-the-art techniques and undergoes stringent quality control measures to guarantee batch-to-batch consistency. It is supplied in a convenient format, ready for immediate use, and is compatible with various experimental protocols.

In summary, the ACHR ALPHA3 Polyclonal Antibody is a superior tool for the investigation of the ACHR alpha-3 subunit. Its exceptional specificity, sensitivity, and reliability make it an indispensable asset for researchers and clinicians alike, facilitating advancements in the understanding and diagnosis of ACHR-related disorders.